Literature DB >> 3563931

Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate.

A G Hendrickx, R Korte, F Leuschner, B W Neumann, A Poggel, P Binkerd, S Prahalada, P Günzel.   

Abstract

Two sex steroid compounds which have been used clinically for parenteral supportive therapy of pregnancy were examined for embryotoxic effects in rhesus and cynomolgus macaques. Hydroxyprogesterone caproate (HPC) alone or in combination with estradiol valerate (EV) were administered intramuscularly (i.m.) to pregnant monkeys at 7-day intervals between 20 and 146 days of gestation and fetuses were examined following cesarean section at 150 +/- 2 days. HPC alone was tested in both species at doses ranging from 0.01 X to 10 X the human dose equivalent (HDE); only rhesus monkeys were exposed to the HPC + EV combination at 0.1 X to 10 X HDE. Total embryolethality resulted following the administration of HPC alone and combined with EV at 1 X and 10 X HDE in rhesus monkeys; the level of abortions in cynomolgus monkeys exposed to HPC (0.1 X to 1 X HDE) was comparable to controls. A small number of nonspecific malformations and developmental variations observed in cynomolgus fetuses after HPC exposure were considered to be incidental findings. No anomalies were found in surviving rhesus monkey fetuses treated with HPC + EV. The results indicate that long-term in utero exposure to the progestin, HPC, alone or in combination with EV in rhesus and cynomolgus monkeys, is embryolethal but not teratogenic at doses up to ten times the human therapeutic dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3563931     DOI: 10.1002/tera.1420350116

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  6 in total

Review 1.  Non-clinical studies of progesterone.

Authors:  R Sitruk-Ware
Journal:  Climacteric       Date:  2018-05-23       Impact factor: 3.005

Review 2.  Progestin treatment for the prevention of preterm birth.

Authors:  Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield
Journal:  Acta Obstet Gynecol Scand       Date:  2011-06-27       Impact factor: 3.636

3.  In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.

Authors:  Caitlin C Murphy; Piera M Cirillo; Nickilou Y Krigbaum; Barbara A Cohn
Journal:  Am J Obstet Gynecol       Date:  2021-11-09       Impact factor: 10.693

4.  Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.

Authors:  Shringi Sharma; Ewa C S Ellis; Kenneth Dorko; Shimin Zhang; Donald R Mattison; Steve N Caritis; Raman Venkataramanan; Stephen C Strom
Journal:  Drug Metab Dispos       Date:  2010-01-22       Impact factor: 3.922

5.  Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth.

Authors:  Gian Carlo Di Renzo; Lluis Cabero Roura; Fabio Facchinetti; Aris Antsaklis; Gregor Breborowicz; Eduard Gratacos; Peter Husslein; Ronnie Lamont; Anton Mikhailov; Nuno Montenegro; Nebojsa Radunovic; Mike Robson; Stephen C Robson; Cihat Sen; Andrew Shennan; Florin Stamatian; Yves Ville
Journal:  J Matern Fetal Neonatal Med       Date:  2011-03-02

6.  Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.

Authors:  Alex C Vidaeff; Michael A Belfort
Journal:  Patient Prefer Adherence       Date:  2013-07-11       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.